You are here

  • Home
  • Archive
  • Volume 25, Issue Suppl 1
  • 1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

Citation Tools

Article menu
Download PDFPDF
Section 1: Introductory statements and governance
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Román AF, Lázaro CB, Fernández JL, et al
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting
European Journal of Hospital Pharmacy 2018;25:A2-A3.